2604.01816 Subgroup Disproportionality Analysis of Serious Adverse Events Associated with Semaglutide in the FDA Adverse Event Reporting System (FAERS): A Sex- and Age-Stratified Pharmacovigilance Study
**Background:** Semaglutide (Ozempic®/Wegovy®/Rybelsus®), a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has seen rapid uptake for type 2 diabetes and obesity management. Post-marketing surveillance for heterogeneous safety signals across demographic subgroups remains an active area of research.